Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Daiichi Sankyo
McKinsey
Covington
Johnson and Johnson
QuintilesIMS
Argus Health
Mallinckrodt
US Army

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,741,920

« Back to Dashboard

Which drugs does patent 8,741,920 protect, and when does it expire?

Patent 8,741,920 protects ZELBORAF and is included in one NDA.

This patent has twenty-six patent family members in fifteen countries.
Summary for Patent: 8,741,920
Title:Process for the manufacture of pharmaceutically active compounds
Abstract: The present invention relates to a composition comprising the compound of formula (1), ##STR00001## and the compound of formula (B), ##STR00002##
Inventor(s): Hildbrand; Stefan (Gelterkinden, CH), Mair; Hans-Juergen (Loerrach, DE), Radinov; Roumen Nikolaev (West Caldwell, NJ), Ren; Yi (Shanghai, CN), Wright; James Anderson (Cedar Grove, NJ)
Assignee: Hoffmann-La Roche, Inc. (Nutley, NJ)
Application Number:13/613,017
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,741,920

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,741,920

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
09167054Aug 3, 2009
09175101Nov 5, 2009

Non-Orange Book US Patents Family Members for Patent 8,741,920

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,329,724 Process for the manufacture of pharmaceutically active compounds ➤ Try a Free Trial
8,530,661 Process for the manufacture of pharmaceutically active compounds ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,741,920

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010280848 ➤ Try a Free Trial
Brazil 112012002251 ➤ Try a Free Trial
Canada 2768632 ➤ Try a Free Trial
China 102574799 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Farmers Insurance
Julphar
US Department of Justice
Queensland Health
QuintilesIMS
Merck
Fish and Richardson
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.